Literature DB >> 3383883

Prognostic implications of transient--predominantly silent--ischaemia in patients with unstable angina pectoris.

T von Arnim1, H W Gerbig, W Krawietz, B Höfling.   

Abstract

The occurrence of unstable angina pectoris, despite medical treatment, is generally regarded as an ominous prognostic sign and an indication for invasive diagnosis and revascularization. We investigated 38 consecutive patients with severe unstable angina with a mean of 2.5 days of continuous two-channel, frequency modulated Holter monitoring for ST segment analysis. In 16 patients, transient ischaemic episodes (more than 0.1 mV lasting more than 1 min) occurred despite maximal medical treatment: 82% of the episodes were silent. Compared to the 22 patients without ischaemic episodes there were no significant differences in prevalence of risk factors, numbers of vessels diseased (69% vs. 74% triple-vessel disease) or ejection fraction (54 +/- 15% vs. 53 +/- 16%). The 30-day prognosis, however, varied: of 16 patients with ischaemic episodes, 14 (88%) had a subsequent cardiac event (death, AMI, PTCA or CABG) compared to only 10 of 22 patients (45%) without ischaemic episodes (P less than 0.02 for all events, P less than 0.1 for death/AMI only). Transient ischaemic episodes, predominantly silent, are frequent in patients with severe unstable angina. Objective evidence of ongoing ischaemia despite medical treatment has a guarded short-term prognosis. 'Stabilization' of unstable angina may be incomplete as long as transient ischaemia at rest can still be detected.

Entities:  

Mesh:

Year:  1988        PMID: 3383883     DOI: 10.1093/oxfordjournals.eurheartj.a062521

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review.

Authors:  C Michael Gibson; Lauren N Ciaglo; Matthew C Southard; Shaun Takao; Caitlin Harrigan; Jason Lewis; Jason Filopei; Michelle Lew; Sabina A Murphy; Jacqueline Buros
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

2.  Prognostic value of continuous ST-segment monitoring in patients with non-ST-segment elevation acute coronary syndromes.

Authors:  Carlos Aguiar; Jorge Ferreira; Ricardo Seabra-Gomes
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

Review 3.  [Significance of silent myocardial ischemia for identification and optimal therapy of patients with latent coronary heart disease. Is there a marker for prognostic indication for PTCA?].

Authors:  D Hering; H P Schultheiss; D Horstkotte
Journal:  Herz       Date:  1999-02       Impact factor: 1.443

4.  Clinical and detailed angiographic findings in patients with ambulatory electrocardiographic ischemia without critical coronary narrowing: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.

Authors:  B L Sharaf; M G Bourassa; R P McMahon; C J Pepine; B R Chaitman; D O Williams; R F Davies; M Proschan; C R Conti
Journal:  Clin Cardiol       Date:  1998-02       Impact factor: 2.882

5.  Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram.

Authors:  D J Patel; D R Holdright; C J Knight; D Mulcahy; B Thakrar; C Wright; J Sparrow; M Wicks; W Hubbard; R Thomas; G C Sutton; G Hendry; H Purcell; K Fox
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

6.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

7.  Prognostic significance of transient ST segment changes after coronary artery bypass surgery: a long-term (4-10 year) follow up study.

Authors:  D Patel; D Mulcahy; N Curzen; A Sullivan; D Cunningham; J Sparrow; C Wright; A Quyyumi; K Fox
Journal:  Br Heart J       Date:  1993-10

Review 8.  Can we really justify the treatment of silent ischemia in 1992? No!

Authors:  D Mulcahy; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.